Aligos Therapeutics, Inc. (ALGS) company profile
Close on Nov 12, 2026Market cap $24.73MP/E –Yield –
About Aligos Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company that focuses on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections. Its drug development pipeline targets conditions such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections. Key drug candidates in development include pevifoscorvir sodium for chronic HBV infection, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections. The company’s potential customers and end users include patients suffering from viral infections and liver disorders, as well as collaboration and licensing partners such as Xiamen Amoytop Biotech Co., Ltd.
The company operates clinical development programs across multiple global jurisdictions, conducting studies in the United States and internationally, including clinical and preclinical collaboration rights in China, Taiwan, Hong Kong, and Macau. Aligos Therapeutics maintains its principal executive offices and headquarters in South San Francisco, California.
Summary of the business section of Aligos Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Aligos Therapeutics, Inc.
- Headquarters
- South San Francisco, CA
- Address
- One Corporate Dr., 2nd Floor 94080
- Phone
- (800) 466-6059
- Website
- aligos.com
- Employees
- 82, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Francisco, California
Stock & identifiers
- Ticker
- ALGS
- Exchange
- Nasdaq
- IPO date
- Oct 19, 2020
- Shares outstanding
- 12M, Aug 3, 2026
- Public float
- $19.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Aug 19, 2024
- SEC CIK
- 1799448
- CUSIP
- 01626L204
- ISIN
- US01626L2043
- FIGI
- BBG00QX7QH68
- Share class FIGI
- BBG00QX7QH77
- LEI
- 549300UU2UJIKJYX0S67
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lawrence Blatt | President and CEO, Director | 1,866,092 |
| Nikhil Aneja | Principal Accounting Officer | – |
| Julian A. Symons | See Remarks | 394,064 |
| Lesley Ann Calhoun | See Remarks | – |
| Margarita Chavez | Director | – |
| James Paul Scopa | Director | 183,083 |
| Carole Nuechterlein | Director | 11,025,941 |
| Heather Preston | Director | – |
| Bridget A. Martell | Director | – |
| Peter Hirth | Director | 59,549 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Lawrence M. Blatt President and Chief Executive Officer | $651.72K | $3.01M | $371.48K | $19.04K | $4.06M | +90% |
| Lesley Ann Calhoun Executive Vice President, Chief Operating Officer and Chief Financial Officer | $502.00K | $874.93K | $190.76K | $12.00K | $1.58M | +55% |
| Julian Symons Executive Vice President, Chief Scientific Officer | $492.76K | $384.55K | $189.22K | $12.00K | $1.08M | +29% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 19, 2020
- Offer price
- $15.00
- Securities offered
- 10,000,000
- Gross proceeds
- $150.00M
- Exchange
- Nasdaq
- First trading day
- Oct 16, 2020
- First-day close
- $14.85-1.0%
- Lock-up ends (est.)
- Apr 14, 2021
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 82 full-time employees, including 64 employees engaged in research and development.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 31, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 22, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 7, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 19, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?